INTRODUCTION {#S1}
============

The World Health Organization (WHO) estimates that more than half of the world's population is at risk for contracting a vector-borne disease. Mosquitoes are the most common insect vector, and they transmit the flaviviruses West Nile virus (WNV), dengue virus (DENV), and Zika virus (ZIKV). *Culex* spp. are important mosquito vectors and were the most frequently infected with WNV in the United States in 2017 ([@R16]). Since 1999, WNV infection has caused disease in the 48 continental states, frequently resulting in mild febrile symptoms. In more extreme cases, WNV causes neuroinvasive infection with severe complications and long-term patient consequences, including paralysis ([@R87]). In 2017, the Centers for Disease Control and Prevention (CDC) reported 2,097 cases of human WNV infection in the United States, with 68% being classified as neuroinvasive ([@R16]). DENV affects 390 million people worldwide each year ([@R7]). ZIKV, another arbovirus with significant health impacts, was originally confined to small outbreaks but expanded rapidly to more than 30 countries between 2015 and 2016 ([@R110]). Significantly, there are currently no post-exposure therapeutics or effective vaccines against WNV, DENV, or ZIKV, indicating an unmet need in public health.

Insects use broadly antiviral signaling pathways to respond to virus infection, most notably the RNAi response and the JAK/STAT pathways. *Drosophila melanogaster* activates RNAi as an innate immune response to DNA and RNA viruses ([@R12]; [@R113]), specifically to WNV ([@R18]), DENV ([@R71]), and ZIKV ([@R41]). Subsequently it was shown that the RNAi pathway responds to WNV subtype Kunjin virus (WNV-Kun) infection in *Cx. quinquefasciatus* adult females ([@R86]). Studies using *D. melanogaster* found that RNAi pathway components communicate with non-canonical signaling proteins. For example, [@R25] demonstrated that the gene *vago* is induced by *Drosophila* C virus (DCV) infection in a Dicer-2 (Dcr2)-dependent manner, and the transcription factor FoxO binds to the promoter regions of the RNAi components Dcr2, Argonaute 1 (AGO1), and AGO2 ([@R103]) during arboviral infection. Notably, WNV, DENV ([@R98]), and WNV-Kun ([@R69]) generate subgenomic flavivirus RNA (sfRNA) to antagonize the RNAi response and enhance virus survival. In addition, *D. melanogaster* uses the JAK/STAT pathway to respond to many RNA viruses, including DCV, cricket paralysis virus (CrPV), Sindbis virus (SINV) ([@R49]), and ZIKV ([@R41]), as well as the DNA virus invertebrate iridescent virus 6 (IIV-6) ([@R116]). The JAK/STAT pathway is activated when secreted cytokines of the unpaired (upd) family engage the cell surface receptor domeless (dome) ([@R13]; [@R40]). When activated, dome signals through the tyrosine kinase hopscotch (hop) ([@R9]) leading to phosphorylation of the transcription factor Stat92E ([@R121]). Stat92E controls the induction of genes that regulate cell proliferation, organismal growth, stem cell renewal, development, and immunity ([@R2]). During viral infection in *D. melanogaster*, Stat92E induces *vir-1* ([@R26]) and *Turandot M (TotM)* ([@R49]), whose protein products have antiviral activity. *Aedes aegypti* uses the JAK/STAT pathway to respond to the flaviviruses WNV, DENV, and yellow fever virus (YFV) ([@R22]), and JAK/STAT signaling is responsive to WNV infection in *Cx. quinquefasciatus* cells ([@R85]). Although it is known that the RNAi and JAK/ STAT responses are important for controlling arboviral infection in insects, it is not fully understood how these pathways communicate with each other. Indeed, arboviruses are controlled by a number of different host responses, including 5′ to 3′ RNA decay ([@R68]), the *Vago*-mediated response, and the Dcr2-mediated response ([@R73]). However, there may be additional, as yet unidentified, signaling components that contribute to the JAK/STAT or RNAi pathways for an integrated antiviral immune response.

Genetic variation in the human population contributes to disease progression for WNV ([@R8]; [@R94]), DENV ([@R82]; [@R117]), and ZIKV ([@R96]). WNV causes symptoms in only 20% of infected individuals, ([@R38]), with two-thirds of those cases becoming neuroinvasive ([@R16]), DENV manifests in approximately 25% of individuals ([@R7]), and ZIKV is symptomatic in 18% of individuals ([@R28]). Therefore, there is power in using genetic screens to uncover potential risk factors or gene mutations that contribute to flavivirus infection. For example, a genetic screen in humans revealed a SNP in *OAS1* that is associated with symptomatic WNV infection ([@R8]). [@R93], [@R94]) also identified mutations in equine *OAS1* that are associated with WNV disease. Similarly, genetic screens can be used to identify pathways that control innate immune responses or viral load in the arthropod vector ([@R51]). Considering the remarkable genetic diversity of insect viruses ([@R58]; [@R115]), the identification of antiviral pathways in insect vectors is important in understanding viral escape mechanisms or entry points and the development of viral control methods ([@R64])

In this study, we used the *Drosophila* Genetic Reference Panel (DGRP), a fully sequenced, inbred panel of fly lines derived from a natural population ([@R63]), to perform a pathway-unbiased screen for natural genetic variants associated with WNV-Kun infection. Through our screen, we found that the insulin-like receptor (*InR*) was necessary for host survival to WNV-Kun. Because mosquitoes are the natural vector for WNV-Kun and other flaviviruses, we leveraged fly genetics to investigate the insulin-mediated host response and address a relevant problem in global health. We determined that priming insect cells with vertebrate insulin activates insulin signaling through Akt and ERK and induces prolonged transcription of JAK/STAT-mediated antiviral genes. The effect of insulin priming was antiviral in both flies and mosquitoes and antiviral to other flaviviruses, namely ZIKV and DENV. This work identifies insulin signaling as a component of insect immunity to arboviral infection and demonstrates that insulin signaling works cooperatively with known antiviral immune pathways for host protection.

RESULTS {#S2}
=======

We used the DGRP ([@R63]) and a corresponding genome-wide association study (GWAS) ([@R19], [@R20]; [@R57]) to determine how natural genetic variation in flies can lead to inter-individual differences in survival during viral infection. The DGRP has been used to identify novel genes that respond to endoplasmic reticulum stress ([@R19]), bacterial infection ([@R10]; [@R43]; [@R114]), and lead toxicity ([@R127]). Unbiased GWAS is informative in determining the genes associated with a particular phenotype and can identify novel genes connected with the phenotype of interest ([@R104]). We performed our screen using the naturally attenuated WNV subtype Kunjin virus (WNV-Kun), which has high sequence identity to the lineage I WNV-New York 1999 strain ([@R54]) and can infect *D. melanogaster* ([@R122]).

We infected female flies from 94 of the DGRP lines with 10^4^ plaque-forming units (PFUs) of WNV-Kun by intrathoracic injection ([@R122]) and determined their mortality rates compared with flies treated with buffer only (mock infection) ([Figure 1A](#F1){ref-type="fig"}). In this experiment, we used fly lines that were free of the endosymbiont *Wolbachia* because infection with this organism can protect against RNA virus infection ([@R108]). We monitored survival daily for 30 days and calculated the hazard ratio as a metric of survival ([Figure 1B](#F1){ref-type="fig"}). We then used the log of the hazard ratio as the quantitative phenotype for the GWAS ([Table S1](#SD1){ref-type="supplementary-material"}), as described previously ([@R19]), and identified a set of genome-wide suggestive variants (nominal p \< 5 × 10^−5^; [Table S2](#SD1){ref-type="supplementary-material"}), including *InR*. Next, we performed gene set enrichment analysis (GSEA) ([Figure 1C](#F1){ref-type="fig"}) to identify groups of gene variants that were functionally enriched. Input for GSEA consisted of the gene and p value associated with each variant from the entire dataset. Given a defined set of genes annotated with a certain Gene Ontology (GO) function, GSEA determines how members of a GO category are distributed throughout the list of genes ranked by p value. GO categories enriched at the top of the list functionally describe the phenotype of the gene set ([@R106]). In the GO category regulation of cell proliferation (GO: 0008284), we identified genes that were previously shown to play a role in fly immunity to RNA virus infection via the JAK/STAT pathway (orange boxes), namely, *Stat92E*, *dome*, *upd3*, and *caudal* (*cad*) ([@R126]). In addition to *InR*, we identified a number of insulin-like peptides (*ilps*) that were part of the functionally enriched GO categories female mating behavior (GO: 0060180) and hormone activity (GO: 0005179) (blue boxes). Functional enrichment of these *ilps* supported a role for insulin signaling in the antiviral immune response.

We selected *upd3*, *Stat92E*, *hop*, and *InR* for validation but also included *tak1* (TGFβ-activated kinase 1) and *egfr* (epidermal growth factor receptor) on the basis of previously identified roles for these genes in RNA virus infection ([@R118]). *Vir-1* is induced downstream of the JAK/STAT pathway ([@R49]) and was used as a surrogate to validate this pathway. Fly lines with these genes deleted or knocked down by RNAi were infected with WNV-Kun. Because *upd2* and *upd3* have redundant roles ([@R49]), we selected a line with mutations in both *upd2* and *upd3* for these analyses. Mortality rates for each genotype during WNV-Kun infection were compared with mock-infected (buffer only) controls. We used hazard ratio as a metric of survival because this value normalizes the mortality rates during virus infection to the mock-infected group and accounts for backgrounds that have different responses to mock infection. As expected on the basis of previous studies, JAK/STAT pathway mutants were susceptible to WNV-Kun infection on the basis of increased mortality (p \< 0.05, hazard ratio \> 1) in *upd*^*Δ2*^*upd*^*Δ3*^ and *hop*^*3*^ mutants, while the control line *y*^*1*^*w*^*1*^ did not display significant mortality ([Figures 2A](#F2){ref-type="fig"}--[2C](#F2){ref-type="fig"}). Viral titers in *Stat92E*^*HJ*^ and *vir-1*^*KG03668*^ mutants were also increased at 5 days post-infection relative to controls, though not significantly ([Figure 2D](#F2){ref-type="fig"}). Our data confirmed that knockdown of *InR* by RNAi ([Figure S1](#SD1){ref-type="supplementary-material"}) or *tak1*^*2527*^ mutation increased susceptibility to WNV-Kun infection ([Figure 2E](#F2){ref-type="fig"}; [Figure S2A](#SD1){ref-type="supplementary-material"}), whereas the *egfr*^*t1*^ mutation, in contrast, did not display significant mortality ([Figure S2B](#SD1){ref-type="supplementary-material"}). Thus, we validated DGRP candidate genes *InR* and *tak1* as well as JAK/STAT pathway genes previously associated with RNA virus infection.

On the basis of validation of *InR* and the identification of *ilps* using GO analysis, we also determined that an *ilp7*^*1*^ mutant is more susceptible to WNV-Kun infection compared with the control *w*^*1118*^ background ([Figure 2F](#F2){ref-type="fig"}). The *D. melanogaster* genome encodes for 8 ilps ([@R79]), and *ilp7* is the most conserved of the fly ilps and the only *ilp* that is truly orthologous to a mosquito *ilp* ([@R34]). Because mosquitoes are exposed to exogenous insulin during a blood meal, and the aim of this work is to better understand the vector-host response during flavivirus infection, we subsequently tested the effects of insulin on the activation of Akt and WNV-Kun replication in *D. melanogaster* S2 cells and on virus replication in adult flies. The insulin signaling pathway in *D. melanogaster* is initiated by ilps binding to InR, which induces a phosphorylation cascade through the signaling protein chico, with subsequent bifurcation through two pathways, one of which is dependent on activation of PI3K (phosphoinositide 3-kinase), PDK1 (pyruvate dehydrogenase kinase 1), and Akt ([@R90]) and a second that is dependent on the activation of MAPK/ERK with feedback between the two branches (reviewed by [@R62]). In addition to *D. melanogaster* ilps, the *D. melanogaster* InR has high affinity for bovine ([@R88], [@R89]) and human insulin ([@R120]), and the binding of vertebrate insulin to the fly InR mediates the same signaling pathways ([@R120]). As in mosquitoes ([@R59]), the InR is expressed in the midgut and epidermis of *D. melanogaster* larva ([@R30]), and the midgut of adult flies ([@R17]). In *D. melanogaster* S2 cells, we observed robust Akt phosphorylation following 8 h of 1.7 μM insulin treatment ([Figure 3A](#F3){ref-type="fig"}). Moreover, we observed reduced transcript levels of *InR* during exogenous insulin treatment, as measured by qRT-PCR ([Figure S3](#SD1){ref-type="supplementary-material"}). This was expected, as insulin-induced activation of Akt-mediated FoxO phosphorylation results in cytoplasmic retention of FoxO and a concomitant loss of FoxO-dependent *InR* induction ([@R90]). After 24 h of continuous insulin treatment prior to infection, WNV-Kun replication was also significantly reduced in S2 cells ([Figure 3B](#F3){ref-type="fig"}), suggesting that insulin-mediated Akt activation stimulated an antiviral response. We tested insulin control of virus replication *in vivo* using WNV-Kun-infected OregonR flies raised on food containing 10 μM insulin. As in S2 cells, viral titer was significantly reduced in insulin-treated flies relative to control flies by 10 days post-infection ([Figure 3C](#F3){ref-type="fig"}). This reduction in systemic replication of WNV-Kun can be attributed to the passage of ingested insulin from the midgut and dissemination to the hemolymph ([Figure 3D](#F3){ref-type="fig"}).

We next investigated signaling crosstalk during insulin-mediated restriction of WNV-Kun replication, with particular focus on JAK/STAT, RNAi, and ERK signaling. We determined that insulin treatment induced prolonged transcription of JAK/ STAT components *upd2*, *upd3*, and *TotM* ([Figures 4A](#F4){ref-type="fig"}--[4C](#F4){ref-type="fig"}), while significant *vir-1* induction was observed during insulin treatment only at 8 h post-infection ([Figure 4D](#F4){ref-type="fig"}). In all cases, these effects were independent of virus infection ([Figures 4A](#F4){ref-type="fig"}--[4D](#F4){ref-type="fig"}). The RNAi components *AGO1*, *AGO2*, and *Dcr2* were induced at early times post-infection during insulin treatment ([Figures 4E](#F4){ref-type="fig"}--[4G](#F4){ref-type="fig"}). However, by 24 h post-infection, *AGO1* induction was significantly reduced during insulin treatment in both control and virus-infected cells ([Figure 4E](#F4){ref-type="fig"}), *AGO2* induction was not observed in either cell treatment at 24 h post-infection ([Figure 4F](#F4){ref-type="fig"}), and *Dcr2* induction persisted only in uninfected cells ([Figure 4G](#F4){ref-type="fig"}). This is consistent with previous work ([@R103]) in that all of these genes are regulated by the transcription factor FoxO but to different relative levels. Furthermore, in *D. melanogaster*, *Argonaute* levels are controlled by microRNA biogenesis, the ubiquitin-proteasome system, and even Dicer itself ([@R101]). This study provides evidence of FoxO-independent regulation of RNAi genes, which may contribute to the varied transcription levels of *AGO1*, *Dcr2*, and *AGO2* in both our studies and those of [@R103]. Together, our results suggested that insulin exposure prolongs the induction of JAK/STAT components, but not RNAi components, indicating that insulin sustains JAK/STAT signaling for the induction of antiviral immune genes.

To validate associations between insulin and JAK/STAT signaling, we examined temporal activation (phosphorylation) of ERK, Akt, and Stat92E in control and WNV-Kun-infected S2 cells with and without insulin treatment. ERK was phosphorylated during insulin treatment, as shown previously ([@R119]), and this phosphorylation was elevated during WNV-Kun infection relative to control (mock; [Figure 4H](#F4){ref-type="fig"}, top row). Akt phosphorylation was induced by WNV-Kun infection, and this was enhanced by insulin treatment relative to control ([Figure 4H](#F4){ref-type="fig"}, third row from top). Low levels of Akt activation were observed during infection in the absence of insulin, which was expected on the basis of previous results showing that WNV activates Akt ([@R100]). In support of a role for JAK/STAT signaling during insulin treatment, we immunoprecipitated Stat92E from whole S2 cell lysate to probe for tyrosine phosphorylation indicative of Stat92E activation. Similar to ERK, Stat92E was activated during WNV-Kun infection, and phosphorylation was enhanced relative to controls (mock) by insulin treatment ([Figure 4H](#F4){ref-type="fig"}, bottom row).

Given that FoxO activity induces expression of RNAi components that are antiviral during CrPV infection ([@R103]), we sought to examine the role of FoxO during insulin treatment and WNV-Kun infection. For this purpose, a cohort of *D. melanogaster* engineered with a FoxO-GFP reporter was reared on food containing 10 μM insulin and infected as third-instar larvae with WNV-Kun. Given that the fat body is an important immune organ during viral infection in flies ([@R56]), we dissected this tissue to visualize FoxO-GFP localization by confocal microscopy from treated and control larvae. As expected on the basis of previous results ([@R90]), insulin treatment increased cytosolic FoxO-GFP, and this effect was independent of WNV-Kun infection ([Figure 4I](#F4){ref-type="fig"}). Hence, insulin treatment results in a loss of FoxO-dependent transcription, consistent with the loss of induction of the RNAi components *AGO1*, *AGO2*, and *Dcr2* at 24 h post-infection during prolonged insulin treatment and infection ([Figures 4E](#F4){ref-type="fig"}--[4G](#F4){ref-type="fig"}).

We next asked if ERK phosphorylation leads to the transcription of JAK/STAT target genes for enhanced antiviral activity during insulin treatment. We determined that *D. melanogaster* S2 cells knocked down for ERK ([Figure 4J](#F4){ref-type="fig"}) no longer express the genes encoding the JAK/STAT ligands *upd2* and *upd3* ([Figures 4K](#F4){ref-type="fig"} and [4L](#F4){ref-type="fig"}) or the transcriptional target *vir-1* ([Figure 4M](#F4){ref-type="fig"}) when treated with 1.7 μM insulin. Additionally, basal expression of *upd3* and *vir-1* is further reduced in cells knocked down for ERK compared with the scrambled double-stranded RNA (dsRNA) control ([Figures 4L](#F4){ref-type="fig"} and [4M](#F4){ref-type="fig"}). Together, these results suggest that ERK activity can control JAK/STAT-mediated anti-viral pathways.

Because mosquitoes are the natural vectors for WNV, we sought to determine whether our findings in *D. melanogaster* would translate to mosquitoes. Akin to the fly model, the InR is expressed in the midgut of *An. stephensi* ([@R59]) and in the WNV vector *Cx. quinquefasciatus* ([@R80]). Additionally, bovine insulin binds the *Aedes aegypti* InR ([@R14]), and human insulin persists in the *An. stephensi* midgut as intact peptide for up to 30 h after feeding and passes through the midgut into the mosquito body (including the head, thorax, and abdomen), where it can persist intact for at least 48 h after feeding ([@R27]). Consistent with these observations, we determined that insulin treatment of *Cx. quinquefasciatus* Hsu cells, *Ae. aegypti* Aag2 cells, and *Ae. albopictus* C6/36 cells activated Akt ([Figures 5A](#F5){ref-type="fig"}--[5C](#F5){ref-type="fig"}) and reduced titers of WNV-Kun relative to control, untreated cells ([Figures 5D](#F5){ref-type="fig"}--[5F](#F5){ref-type="fig"}). This antiviral effect was not limited to WNV-Kun in that insulin treatment reduced the titers of two additional flaviviruses, ZIKV and DENV, in C6/36 cells ([Figures 5G](#F5){ref-type="fig"} and [5H](#F5){ref-type="fig"}). Notably, C6/36 cells lack an RNAi response ([@R11]), demonstrating that an RNAi response is not required for insulin-mediated antiviral activity. This is in contrast to Aag2 cells, which are RNAi competent ([@R99]) and display reduced WNV-Kun replication during insulin treatment, further suggesting that the effects of insulin are independent of RNAi-mediated antiviral activity. Finally, WNV-Kun titer was increased significantly in *Ae. albopictus* C6/36 cells treated with 10 μM MEK/ERK inhibitor U0126, and this treatment reversed the effects of insulin on virus replication ([Figure S4](#SD1){ref-type="supplementary-material"}), affirming that virus- and insulin-induced ERK activation ([Figure 4H](#F4){ref-type="fig"}, top row) is functionally important in the regulation of virus replication in mosquito cells ([Figure S4](#SD1){ref-type="supplementary-material"}).

Last, we tested the effects of insulin treatment on WNV-Kun replication in *Cx. quinquefasciatus* adult females. Age-matched 6- to 9-day-old adult female mosquitoes were infected with WNV-Kun via blood meal in the presence or absence of insulin and collected at 1, 5, and 10 days post-infection ([Figure 6A](#F6){ref-type="fig"}). Mosquitoes that did not blood feed were excluded from subsequent analyses. We selected 170 pM bovine insulin, as this dose is within the physiological range in humans ([@R24]) and activates insulin signaling and alters *Plasmodium falciparum* development in *Anopheles stephensi* ([@R83]). Similar to our results in *D. melanogaster*, we observed that insulin treatment led to decreased *R2D2* and *Dcr2* induction in insulin-fed control mosquitoes ([Figures 6B](#F6){ref-type="fig"} and [6C](#F6){ref-type="fig"}), suggesting a reduced RNAi response in the context of increased *STAT* expression in insulin-fed infected mosquitoes ([Figure 6D](#F6){ref-type="fig"}). Furthermore, WNV-Kun *env* and *NS5* gene expression levels were reduced in insulin-fed mosquitoes by 10 days post-infection ([Figures 6E](#F6){ref-type="fig"} and [6F](#F6){ref-type="fig"}). Although insulin-induced *STAT* expression was significant at 1 day post-infection ([Figure 6C](#F6){ref-type="fig"}), markers of virus infection were not significantly reduced until 10 days post-infection ([Figures 6E](#F6){ref-type="fig"} and [6F](#F6){ref-type="fig"}). Intriguingly, numerous reports of WNV infection in mammalian cells indicate that WNV non-structural proteins, including NS5 for which expression increases over time in both control and insulin-treated mosquitoes ([Figure 6F](#F6){ref-type="fig"}), can interfere with JAK/STAT signaling ([@R35]; [@R55]; [@R72]), suggesting an explanation for the delay in observed effects of insulin on virus infection. Moreover, because of a point mutation in NS5, WNV-Kun displays reduced STAT antagonism ([@R55]), which allows a more robust JAK/STAT host response during infections with this strain compared with the virulent WNV strain NY99. Collectively, these results suggest that vertebrate insulin ingested with the blood meal reduces viral RNA levels in the vector, perhaps through a STAT-mediated immune response that enables the vector to survive infection and transmit the virus to another host.

DISCUSSION {#S3}
==========

In the work presented here, we used the DGRP to investigate an antimicrobial host response to flaviviral infection and identified *InR*, along with other known antiviral response mediators, as components of the *D. melanogaster* response to WNV-Kun infection. We demonstrated that vertebrate insulin activates insulin and JAK/STAT signaling for a net antiviral effect in *D. melanogaster* cells. Moreover, an analogous antiviral effect is detectable in *Cx. quinquefasciatus*, *Ae. aegypti*, and *Ae. albopictus* cells, as well as *Cx. quinquefasciatus* females, and this insulin-dependent response is broadly antiviral to other flaviviruses, including DENV and ZIKV. Collectively, our data suggest that insulin activates known immune response pathways *in vitro* and *in vivo* for overall host restriction of flavivirus infection.

Mechanistically, we show that InR mediates its broad anti-flaviviral activity by selectively potentiating the JAK/STAT but not RNAi response. We show that ERK is activated in the context of FoxO inactivation and cytosolic localization, and we hypothesize that ERK links insulin signaling to the JAK/STAT pathway ([Figure 7](#F7){ref-type="fig"}). Among elements related to JAK/STAT signaling in flies, upd2 controls ilp secretion by the fat body during the fed state ([@R91]). The JAK/STAT-dependent genes *vir-1* and *TotM* are induced during RNA virus infection in *D. melanogaster*, with rapid-kill viruses (\<10 days) inducing a *vir-1* response and slow-kill viruses inducing a *TotM* response ([@R49]). WNV-Kun typically kills flies slowly, substantiating the prolonged *TotM* induction ([Figure 4C](#F4){ref-type="fig"}) that we observed. This is in agreement with the findings of [@R41], in which a non-lethal ZIKV infection (strain MR755) induces a *TotM*, but not a *vir-1*, response. Given that MEKK1 signaling can contribute to *TotM* induction ([@R15]), ERK activation could prolong *TotM* induction during insulin priming to enhance an overall antiviral effect through JAK/STAT. In addition, we observed that ERK activation by insulin was induced concurrently with Stat92E phosphorylation ([Figure 4H](#F4){ref-type="fig"}) and directly regulated virus replication ([Figure S4](#SD1){ref-type="supplementary-material"}), while FoxO activation and expression levels of RNAi components were reduced, suggesting that insulin activates the JAK/STAT pathway and ERK to control WNV-Kun replication. Interestingly, we observed that the antiviral RNAi response was not reliant on insulin signaling. This may be due in part to the fact that insulin signaling and a nutrient-rich environment lead to FoxO phosphorylation and reduced induction of FoxO target genes, such as *InR* and those that encode RNAi machinery ([@R90]; [@R103]). Although these conditions would lead to increased growth and lifespan regulation in *D. melanogaster* ([@R32]; [@R45]) and mosquitoes ([@R4]; [@R47]), in the context of viral infection, they could be detrimental because of decreased antiviral RNAi activity. However, our results support a model in which insulin-induced JAK/STAT signaling compensates for the loss of RNAi activity. Importantly, we observed an insulin-mediated antiviral phenotype in both the RNAi-competent *Ae. aegypti* Aag2 cells ([@R99]) and RNAi-deficient *Ae. albopictus* C6/36 cells ([@R11]), thus providing a natural experiment in support of our inference that the insulin-dependent mosquito antiviral response is not mediated through RNAi.

We have determined that even hormonal levels of bovine insulin alter the host response enough to reduce WNV-Kun levels by a significant amount. Although this initially would seem disadvantageous to the pathogen in that there is apparently a lower capacity for virus transmission, the insulin-mediated host response may be protective enough to limit, but not eliminate, infection. If this were to occur, the infected vector could live long enough to feed again and transmit the virus to a new vertebrate host. This indicates a potential trade-off between immune response and pathogen/vector survival. In studies of potential trade-offs for the vector mosquito, WNV infection in *Cx. tarsalis* caused no change in survival but decreased fecundity and increased the feeding rate ([@R105]). In contrast, WNV-infected *Cx. pipiens* had no change in survival, fecundity, or feeding rate, but resistance to infection seemed to be associated with a fitness cost ([@R21]). These studies suggest that the vector's response may affect the ability of the pathogen to infect a subsequent host. More work is needed to understand whether the insulin-mediated immune response in mosquitoes and reduction in flavivirus titer is beneficial to vertebrates, in that overall virus concentration is reduced in the insect and the capacity for transmission is lower, or if this effect is detrimental in that insulin reduces infection, resulting in mosquitoes that live longer and transmit the virus during subsequent blood feedings. These trade-offs could vary between mosquito species and between different flaviviruses.

Prior to our studies, the insulin signaling pathway had not been specifically linked to host immunity to WNV. Intriguingly, however, diabetes mellitus has been shown to increase risk for WNV infection ([@R78]), and in mouse models of the disease, leukocyte and T cell recruitment is decreased and WNV replication and neuroinvasiveness are increased in the absence of insulin ([@R52], [@R53]). These observations are mirrored in malaria parasite infection. Specifically, a higher percentage of *An. stephensi* becomes infected following feeding on *P. falciparum*-infected type 2 diabetic mice compared with mosquitoes that fed on control animals, suggesting that diabetic mice are more efficient at infecting mosquitoes ([@R84]). Indeed, insulin signaling has previously been implicated in immunity to parasites, bacteria, and viruses in both insects and mammals. In *D. melanogaster*, [@R75] determined that insulin signaling is networked to peptidoglycan receptor signaling for an antibacterial immune response. In *An. stephensi*, overexpression of activated Akt in the midgut blocked *P. falciparum* infection ([@R23]). In human cells, Akt signaling has been connected to the immune response to the flavivirus hepatitis C virus (HCV) ([@R5]), and virus-induced disruption of insulin signaling was observed to increase HCV replication ([@R125]). A variety of studies suggest that insulin signaling-dependent activation of ERK contributes to this antiviral effect. In particular, ERK is activated in response to DENV in human cells ([@R102]), by WNV in mouse cells ([@R97]), and by vesicular stomatitis virus (VSV), SINV, and DCV in *D. melanogaster* cells and in adult flies ([@R119]). Furthermore, [@R119] showed that insulin- and ERK-dependent signaling restricts DCV and SINV infection in *D. melanogaster* and *Ae. aegypti* cells. Intriguingly, recent results indicate that the endosymbiont *Wolbachia* affects insulin signaling in mosquitoes. That work showed that *Wolbachia* downregulates *Aedes InR* expression and reduces DENV and ZIKV replication ([@R39]). Here, we investigated the role of exogenous insulin in *Wolbachia*-free insects and insect cells during flavivirus infection. Future studies of the effects of exogenous insulin signaling on flavivirus super-infection in *Wolbachia*-infected insects could further clarify insulin coordination of antiviral responses. Collectively, these previous studies and ours affirm that insulin signaling regulates innate immune responses to a broad array of microbial pathogens. Specifically, we propose that insulin integrates ERK and JAK/STAT signaling pathways during the host response to flavivirus infection.

Taken together, our data demonstrate that the *Cx. quinquefasciatus* response to insulin mirrors the *D. melanogaster* response in that JAK/STAT is induced by WNV-Kun infection and is potentiated by insulin in the blood meal, perhaps through ERK signaling. Given this signaling framework and the conservation of this antiviral effect, we have leveraged fly genetics to efficiently identify and validate across species the downstream mechanisms that underlie insulin-dependent inhibition of viral replication. Although we are cognizant of species-specific distinctions that likely exist across an estimated 260 million years of evolution between flies and mosquitoes ([@R3]), we have provided an example of using these two systems in parallel to speed the identification of novel gene targets involved in the regulation of flavivirus infection in vector mosquitoes. Such findings could enhance novel genetic solutions to reduce mosquito-borne infections by targeting insulin signaling with small molecules ([@R123]) or through the use of CRISPR in mosquitoes ([@R31]). With respect to human infections, given that diabetes is a risk factor for flaviviral disease ([@R36]; [@R67]) and that ERK- and Akt-dependent pathways control viral replication in human cells as noted above, *D. melanogaster* models of diabetes ([@R46]; [@R74]) could extend our understanding of the mechanisms of increased risk for flavivirus infection and guide the identification of strategies to lessen human disease burden.

STAR★METHODS {#S4}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S5}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Alan Goodman (<alan.goodman@wsu.edu>). This study did not generate new unique reagents.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S6}
--------------------------------------

### Fly Lines and Genetics {#S7}

A genetic screen was completed using the available fly lines from the DGRP ([@R63]) that lack the endosymbiont *Wolbachia* (Bloomington *Drosophila* Stock Center). RNAi knockdown of *InR* was achieved by crossing a driver line for actin (actin5C-GAL4) with a fly line containing a cassette expressing the UAS for actin and dsRNA for the *InR* gene. Progeny flies were knocked-down for *InR* if they contained the actin5C-GAL4 driver, and the sibling control flies contained wild-type levels of *InR* if they carried the *CyO* balancer. Knockdown of *InR* was confirmed by qRT-PCR ([Figure S1](#SD1){ref-type="supplementary-material"}). Flies used in the study are listed in the [Key Resources table](#S5){ref-type="sec"}. Flies were maintained on standard cornmeal food (Genesee Scientific \#66--112) at 25°C and 65% relative humidity, and a 12 h/12 h light/dark cycle. Adult flies used in experiments were all females, 2--7 days post-eclosion. Bovine insulin (Sigma 10516) was added to food preparation for a final concentration of 10 μM, within the range described in [@R119]. Dissemination of bovine insulin was determined by dissection of the midguts from five adult flies in PBS ([@R42]). PBS containing the hemolymph and carcasses were also collected, and all tissue was analyzed by western blot using an antibody against bovine insulin (Novus Biologicals NBP2--34260).

### Bioinformatics {#S8}

GWAS analysis was completed as described in [@R19], [@R20]) and [@R57]), using log(hazard ratio) as a metric of mortality ([@R19]). All single nucleotide polymorphism (SNP) coordinates are based on the *D. melanogaster* dm6 genome build. Lines with less than 2% death in the mock-infected group were removed prior to analysis, as described ([@R19]). Gene Set Enrichment Analysis (GSEA) ([@R106]) was performed using all GWAS variant data and their associated p values as previously described ([@R106]). The gene nearest to each variant was assigned the variant's p value and used as GSEA input. While traditional GO analysis uses a set of genes based on a p value cutoff, GSEA examines the entire gene set ([@R29]). A cut-off of p \< 0.01 was used for the GO categories presented in [Figure 1C](#F1){ref-type="fig"}.

### Cells and Virus {#S9}

Vero cells (ATCC, CRL-81) were kindly provided by A. Nicola and cultured at 37°C/5% CO~2~ in DMEM (ThermoFisher 11965) supplemented with 10% FBS (Atlas BiologicalsFS-0500-A) and 1x antibiotic-antimycotic (ThermoFisher 15240062). *Aedes albopictus* C6/36 cells (ATCC, CRL-1660), which are free from persistent WNV, DENV, or ZIKV infection ([@R76]; [@R77]), were cultured at 28°C/5% CO~2~ in RPMI supplemented with 10% FBS (FisherScientific SH3007003HI), 0.15% sodium bicarbonate (ThermoFisher 25080), 1× non-essential amino acids (ThermoFisher 11140), 1× sodium pyruvate (ThermoFisher 11360), and 1× antibiotic-antimycotic. *Culex quinquefasciatus* Hsu cells ([@R44]) were gifted by R. Tesh and cultured at 28°C in L-15 medium (ThermoFisher 11415) supplemented with 10% FBS (FisherScientific SH3007003HI), 10% tryptose phosphate buffer (ThermoFisher 18050), and 1× antibiotic-antimycotic. Hsu cells have been shown to be free of densoviruses, which are found in other mosquito cell lines ([@R81]). S2 cells were cultured as described in [@R1] and are negative for Flock House virus infection. *Aedes aegypti* Aag2 cells (*Wolbachia*-free) were gifted by S. O'Neill and cultured as described in ([@R109]). For insulin priming experiments, culture media with 2% FBS was supplemented with 1.7 μM insulin from bovine pancreas (Sigma 10516), as used previously ([@R124]). Insulin was not cytotoxic to any of the insect cells used ([Figure S5](#SD1){ref-type="supplementary-material"}). For ERK inhibition experiments, culture media was supplemented with 10 μM U0126 in DMSO (Cell Signaling 9903) ([@R83]; [@R107]) 24 hours prior to and during infection.

West Nile virus-Kunjin (strain MRM16) was provided by R. Tesh, passaged twice in Vero cells, and purified by ultracentrifugation. WNV-Kun can be used in arthropod containment level 2 (ACL2) facilities ([@R37]; [@R112]). Zika virus (Paraiba strain) was gifted by S. Best, passaged once in C6/36 cells, and purified by ultracentrifugation. The Paraiba strain was isolated from a human patient during the Brazilian epidemic in 2015 ([@R111]), and is virulent in mice ([@R66]). Dengue virus 2 (New Guinea C strain) was gifted by S. Best. All experiments with a specific virus type utilized the same stock.

### Mosquito Rearing {#S10}

*Culex quinquefasciatus* eggs were originally collected near Johannesburg, South Africa and distributed by the Centers for Disease Control and Prevention by BEI Resources, NIAID, NIH (*Cx. quinquefasciatus*, Strain JHB, Eggs, NR-43025), and mosquitoes were reared following the conditions described by BEI and following [@R48]. Adult female mosquitoes were fed on defibrinated chicken blood (Colorado Serum Company 31141) in hog sausage casing. Adults were provided continuous access to sucrose (JT Baker 4072--01). 6--9 day old adult female mosquitoes were deprived of sucrose 48 hours prior to experimental feedings, as described ([@R70]).

METHOD DETAILS {#S11}
--------------

### Plaque Assay {#S12}

All data showing titers of KUNV, ZIKV, and DENV were determined by standard plaque assay on Vero cells ([@R6]), with the exception of viral RNA levels in mosquitoes, which were determined by qRT-PCR.

### Cytotoxicity of Bovine Insulin {#S13}

Insulin or HEPES buffer control was added to a monolayer of cells in 48-well plates. Cells were collected at various times post-treatment, stained with trypan blue (ThermoFisher 15250--061), and scored as live or dead, as previously described ([@R1]). 8 technical replicates were averaged for each biological replicate.

### Immunoprecipitation and Immunoblotting {#S14}

Protein extracts were prepared by lysing cells with RIPA buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1mM Na~3~VO~4~, 1 mM NaF, 0.1 mM PMSF, 10 μM aprotinin, 5 μg/mL leupeptin, 1 μg/mL pepstatin A). Protein samples were diluted using 2× Laemmli loading buffer, mixed, and boiled for 5 minutes at 95°C. Samples were analyzed by SDS/PAGE using a 10% acrylamide gel, followed by transfer onto PVDF membranes (Millipore IPVH00010). Membranes were blocked with 5% BSA (ThermoFisher BP9706) in Tris-buffered saline (50 mM Tris-HCl pH 7.5, 150 mM NaCl) and 0.1% Tween-20 for 1 hour at room temperature.

Following insulin treatment and virus infection in *D. melanogaster* S2 cells, cells were lysed in RIPA buffer and 100 μg of total protein were immunoprecipitated with an antibody recognizing total Stat92E (Santa Cruz, sc-15708) at 4°C overnight, followed by a 2 hour incubation with Protein A agarose beads (Pierce 22811) at 4°C. Beads were washed three times with NETN buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, and 0.5% NP-40). Beads were boiled for 10 minutes at 95°C and supernatants were subjected to western blotting for P-Tyr (Cell Signaling 8954).

Primary antibody labeling was done with anti-P-Akt (Ser473) (1:2,000) (Cell Signaling 4060), anti-Akt (pan) (1:1,000) (Cell Signaling 4691), ERK (Cell Signaling 4695) (1:1,000), P-ERK (Cell Signaling 4370) (1:2,000), P-Tyr (Cell Signaling 8954S) (1:2,000), or anti-actin (Sigma A2066) (1:10,000) overnight at 4°C. Secondary antibody labeling was done using anti-rabbit (Promega 4011) or anti-goat (Jackson Immunoresearch 705--035-147) IgG-HRP conjugate (1:10,000) by incubating membranes for 2 hours at room temperature. Blots were imaged onto film using luminol enhancer (ThermoFisher 1862124).

### RNA Interference In Vitro {#S15}

Long dsRNA targeting *D. melanogaster* ERK (*rolled*) and non-targeting control dsRNA was synthesized as described in [@R95]. Primers are listed in the [Key Resources table](#T1){ref-type="table"}. dsRNA was transfected into S2 cells as described in [@R65].

### Quantitative Reverse Transcriptase PCR {#S16}

qRT-PCR was used to measure gene mRNA levels in S2 cells and *Cx. quinquefasciatus*. Cells or mosquitoes were lysed with Trizol Reagent (ThermoFisher 15596). RNA was isolated by column purification (ZymoResearch R2050), DNA was removed (ThermoFisher 18068), and cDNA was prepared (BioRad 170--8891). Expression of *D. melanogaster* genes *InR*, *AGO1*, *AGO2*, *Dicer-2*, *upd2*, *upd3*, and *vir-1* were measured using SYBR Green reagents (ThermoFisher K0222) and normalized to *Rp49*. Expression of *TotM* was measured using primer/probe sets for *TotM* (Dm02362087_s1 ThermoFisher 4351372) and normalized to *RpL32* (Dm02151827_g1 (ThermoFisher 4331182), as in [@R49], using TaqMan Universal Master Mix (ThermoFisher 4304437). Expression of the *Cx. quinquefasciatus* genes *CxR2D2*, *CxDcr2*, and *CxSTAT* and of the WNV-Kun *envelope* and *NS5* genes was measured using SYBR Green and normalized to *Cx18S*. The reaction for both SYBR Green and TaqMan samples included one cycle of denaturation at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 15 s and extension at 60°C for 1 minute, using an Applied Biosystems 7500 Fast Real Time PCR System. ROX was used as an internal control. qRT-PCR primer sequences are listed in the [Key Resources table](#T1){ref-type="table"} ([@R25]; [@R60]; [@R85]; [@R92]; [@R103]).

### Larval Infections and Confocal Microscopy {#S17}

Third-instar *D. melanogaster* larvae were washed with PBS, placed in a pool of buffer with WNV-Kun, and pricked with a tungsten needle ([@R42]). Fat bodies were dissected at 4 hours post-infection, fixed, and blocked following [@R61]. Samples were stained with DAPI, mounted onto coverslips using ProLong Diamond Antifade Mountant (Invitrogen P36961), and imaged using a Leica Sp8X confocal microscope.

### Fly Infections {#S18}

2--7 day old adult *D. melanogaster* were anesthetized with CO~2~ and injected intrathoracically with 23 nL of WNV-Kun to achieve a dose of 10,000 PFU/fly, as described ([@R65]; [@R122]). Mock infection was the equivalent of injection with saline. For mortality studies, groups of at least 40 flies were injected and kept in vials containing cornmeal food (Genesee Scientific \#66--112). DGRP survival curves were repeated to verify reproducibility. All survival studies for a specific mutant (e.g., *InR* RNAi or deletion mutants) were repeated and the survival data were combined. Vials were changed every three days. For viral titer experiments, three groups of five flies were collected, homogenized in PBS, and used as individual samples for plaque assay.

### Mosquito Infections {#S19}

WNV-Kun was added to chicken blood washed with RPMI, supplemented with 20% FBS and HEPES buffer or 170 pM insulin ([@R47]; [@R83]), at a final concentration of 1×10^7^ PFU WNV-Kun/mL. The dose was selected as an intermediate between the doses used in [@R50] and [@R85]. Female *Cx. quinquefasciatus* were maintained for three generations and subsequently fed using an artificial mosquito feeder (Chemglass Life Sciences) for 2 hours. Engorged females were separated under CO~2~, placed in 1 gal cartons with continuous access to 10% sucrose, and collected at 1, 5, and 10 days post-infection for analysis. Females that did not feed were excluded from all subsequent analysis.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S20}
---------------------------------------

Results presented as dot plots show data from individual biological units (N = 3--9 replicates) and the arithmetic mean of the data, shown as a black horizontal line. Biological units of adult flies (N = 3--11 replicates) consisted of three to five pooled animals and biological units of mosquitoes (N = 3--6 replicates) consisted of three pooled animals. Results shown are representative of at least duplicate independent experiments, as indicated in the figure legends. All statistical analyses are performed on the biological unit/replicate scale and were completed using GraphPad Prism. Two-tailed unpaired t tests assuming unequal variance were utilized to compare normally distributed pairwise quantitative data. Two-way ANOVA with Tukey's correction for multiple comparisons was used to compare multivariate data. Mann-Whitney tests were utilized to compare distribution-free quantitative data. All error bars represent standard deviation of the mean. Any statistical outliers for experiments were identified using a Grubb's test (α = 0.05) and removed. Survival curves were analyzed by the log-rank (Mantel-Cox) test using GraphPad Prism to determine p values between infected genotypes. When data from independently performed survival experiments are combined for a final curve, the maximum p value among the independent experiments is reported.

DATA AND CODE AVAILABILITY {#S21}
--------------------------

All input phenotypic data (hazard ratios) are provided in [Table S1](#SD1){ref-type="supplementary-material"}. The full output GWAS data generated during this study are available at Mendeley Data (<https://data.mendeley.com/datasets/xwzp5ymp24/3>). This study did not generate code.
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![A Genetic Screen of *D. melanogaster* Identified Candidate Genes Involved in the *D. melanogaster* Response to WNV-Kun\
(A) Schematic of the screen and downstream analysis.\
(B) Survival of each DGRP line, measured by log(hazard ratio).\
(C) Gene set enrichment analysis (GSEA) using genes for all variants and their associated p values from the GWAS. Heatmap data represent GWAS variant p values, while the bar graph indicates the GSEA p value and the number of genes enriched for each GO category in parentheses. Genes indicated in orange boxes are components of the JAK/STAT pathway, and genes indicated by blue boxes are components of the insulin signaling pathway.](nihms-1542969-f0002){#F1}

![Components of the JAK/STAT and Insulin Signaling Pathways Are Necessary for *D. melanogaster* Survival against WNV-Kun Infection\
(A--C) Mutants in the genes (B) *upd2* and *upd3* and (C) *hop* are susceptible to WNV-Kun infection compared with the (A) *y*^*1*^*w*^*1*^ isotype control.\
(D) WNV-Kun titer is higher in *Stat92E* and *vir-1* mutant flies relative to the *y*^*1*^*w*^*1*^ isotype control at 5 days post-infection (\#p \< 0.05, Mann-Whitney test).\
(E) *InR* knockdown and (F) *ilp7*^*1*^ mutant flies are susceptible to WNV-Kun compared with the sibling or background controls. Hazard ratio for each infection group is indicated in parenthesis, and statistical significance from the control group is indicated with an asterisk (\*p \< 0.05, log-rank test).\
Each survival curve represents two (B and C) or three (A, E, and F) independent experiments of \>40 flies that were combined for a final survival curve. For titer results (D), marker shapes represent biological replicates, the bar represents the mean, and error bars represent SDs. Samples for which virus was not detected are indicated by "n.d." Titer data are representative of duplicate independent experiments.](nihms-1542969-f0003){#F2}

![The *D. melanogaster* Insulin Signaling Pathway Is Activated by Vertebrate Insulin, Which Is Antiviral to WNV-Kun\
(A) Akt is phosphorylated and activated in *D. melanogaster* S2 cells when treated with bovine insulin.\
(B) WNV-Kun titer is reduced in S2 cells primed with 1.7 μM bovine insulin for 24 h prior to infection (MOI = 0.01 PFU/cell).\
(C) WNV-Kun titer is reduced in *D. melanogaster* on a diet of 10 μM bovine insulin (\*p \< 0.05, unpaired t test). Open circles represent biological replicates. Horizontal lines or bars represent the mean. Error bars represent SDs.\
(D) Ingested insulin disseminates from the midgut into the hemolymph in flies on a diet of 10 μM bovine insulin.\
Results are representative of duplicate (A and D) or triplicate (B and C) independent experiments.](nihms-1542969-f0004){#F3}

![Insulin Priming Activates Antiviral Pathways in *D. melanogaster*\
(A--G) Induction of genes within the JAK/STAT pathway, (A) *upd2*, (B) *upd3*, (C) *TotM*, and (D) *vir-1*, and the RNAi pathway, (E) *AGO1*, (F) *AGO2*, and (G) *Dcr2*, were measured using qRT-PCR following priming of *D. melanogaster* S2 cells with 1.7 μM insulin and mock or WNV-Kun infection.\
(H) Levels of ERK, Akt, and Stat92E phosphorylation were measured using western blot following insulin treatment and mock or WNV-Kun infection of S2 cells.\
(I) FoxO localization in the larval fat body was determined by confocal microscopy using third-instar larvae on a standard cornmeal diet with or without 10 μM bovine insulin and mock- or WNV-Kun-infected for 4 h.\
(J--M) ERK was knocked down in S2 cells (J), and transcript levels of (K) *upd2*, (L) *upd3*, and (M) *vir-1* were measured using qRT-PCR (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001, ANOVA with correction for multiple comparisons).\
Open circles represent biological replicates. Horizontal black bars represent the mean. Error bars represent SDs. Results are representative of duplicate independent experiments.](nihms-1542969-f0005){#F4}

![Insulin Priming Reduces Flavivirus Titer in *Cx. quinquefasciatus, Ae. aegypti*, and *Ae. albopictus* Cells\
(A--C) Akt is phosphorylated and activated by insulin priming in (A) *Cx. quinquefasciatus* Hsu cells, (B) *Ae. aegypti* Aag2 cells, and (C) *Ae. albopictus* C6/36 cells.\
(D--H) Insulin priming reduces WNV-Kun titer in (D) Hsu, (E) Aag2, and (F) C6/36 cells and (G) Zika virus and (H) dengue virus titer in C6/36 cells (MOI = 0.01 PFU/cell) (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001, unpaired t test).\
Open circles represent biological replicates. Horizontal bars represent the mean. Error bars represent SDs. Results are representative of triplicate independent experiments.](nihms-1542969-f0006){#F5}

![Insulin Activates the Antiviral Response in Adult Female *Cx. quinquefasciatus*\
(A) Schematic illustrating process of age-matching pupae into adults, feeding female mosquitoes a blood meal of chicken blood with or without insulin or WNV-Kun, and collecting adults for analysis post-infection.\
(B--F) Induction of (B) *CxR2D2*, (C) *CxDcr2*, (D) *CxSTAT*, (E) WNV-Kun *envelope* (*env*), and (F) *NS5* genes were measured using qRT-PCR following blood feeding of *Cx. quinquefasciatus* (\*p \< 0.05, unpaired t test; or \#p \< 0.05, Mann-Whitney test).\
Circles represent biological replicates. Bars represent the mean. Error bars represent SDs. Results are representative of duplicate independent experiments.](nihms-1542969-f0007){#F6}

![Schematic of Immune Signaling during Insulin Priming in Insects\
Insulin (red box) binds to the insulin-like receptor (InR), activating a signaling cascade that inhibits FoxO-dependent transcription of RNAi components and reduces RNAi-dependent antiviral immunity. Proposed networked regulation of insulin and JAK/STAT signaling includes activation of ERK downstream of PI3K and increased expression of *upd2/3*, suggesting a control point for insulin-enhanced JAK/STAT signaling. Signaling components denoted by pink stars were important for *D. melanogaster* survival during WNV-Kun infection. Components indicated by orange boxes were induced at the transcript level by insulin treatment, and those indicated by teal boxes were activated at the protein level.](nihms-1542969-f0008){#F7}

  REAGENT or RESOURCE                                                                                       SOURCE                                IDENTIFIER
  --------------------------------------------------------------------------------------------------------- ------------------------------------- ------------------------------------
  Antibodies                                                                                                                                      
  Rabbit monoclonal anti-phospho-Akt (Ser473)                                                               Cell Signaling                        Cat\#4060
  RRID:AB_2315049                                                                                                                                 
  Rabbit monoclonal anti-Akt (pan) (C67E7)                                                                  Cell Signaling                        Cat\#4691
  RRID:AB_915783                                                                                                                                  
  Goat polyclonal anti-Stat (dN-17)                                                                         Santa Cruz                            Cat\#15708
  RRID:AB_661405                                                                                                                                  
  Rabbit monoclonal anti-p44/42 MAPK (Erk1/2) (137F5)                                                       Cell Signaling                        Cat\#4695
  RRID:AB_390779                                                                                                                                  
  Rabbit monoclonal anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E)                           Cell Signaling                        Cat\#4370
  RRID:AB_2315112                                                                                                                                 
  Rabbit monoclonal anti-phospho-Tyr (P-Tyr-1000) MultiMab                                                  Cell Signaling                        Cat\#8954
  RRID:AB_2687925                                                                                                                                 
  Rabbit polyclonal anti-actin                                                                              Sigma                                 Cat\#A2066
  RRID:AB_476693                                                                                                                                  
  Mouse monoclonal anti-insulin                                                                             Novus Biologicals                     Cat\#NBP2--34260
  RRID:AB_2811080                                                                                                                                 
  Anti-rabbit IgG (H+L) HRP conjugate                                                                       Promega                               Cat\#4011
  RRID:AB_430833                                                                                                                                  
  Anti-goat IgG (H+L) HRP conjugate                                                                         Jackson Immunoresearch                Cat\#705--035--147
  RRID:AB_2313587                                                                                                                                 
  Bacterial and Virus Strains                                                                                                                     
  West Nile virus-Kunjin                                                                                    Laboratory of Robert Tesh             MRM16 strain
  Zika virus                                                                                                Laboratory of Sonja Best              Paraiba strain
  Dengue virus 2                                                                                            Laboratory of Sonja Best              New Guinea C strain (BEI NR-84)
  Biological Samples                                                                                                                              
  Chicken Blood                                                                                             Colorado Serum Company                Cat\#31141
  Hog sausage casing                                                                                        C&L Locker Co. (Local butcher)        N/A
  *Culex quinquefasciatus* eggs (Strain JHB)                                                                BEI Resources                         NR-43025
  Chemicals, Peptides, and Recombinant Proteins                                                                                                   
  ERK chemical inhibitor U0126                                                                              Cell Signaling                        Cat\#9903
  Insulin from bovine pancreas                                                                              Sigma                                 Cat\#10516
  T7 RiboMAX Express Large Scale RNA Production System                                                      Promega                               Cat\#P1320
  Cellfectin II                                                                                             ThermoFisher                          Cat\#10362100
  Experimental Models: Cell Lines                                                                                                                 
  *Cercopithecus aethiops*: Cell line Vero                                                                  ATCC                                  CCL-81
  *Aedes albopictus*: Cell line C6/36                                                                       ATCC                                  CRL-1660
  *Culex quinquefasciatus*: Cell line Hsu                                                                   [@R44]                                
  *D. melanogaster*: Cell line S2: S2-DGRC                                                                  Laboratory of Lucy Cherbas            FlyBase: FBtc0000006
  *Aedes aegypti*: Cell line Aag2wMel.tet                                                                   [@R109]                               Laboratory of Scott O'Neill
  Experimental Models: Organisms/Strains                                                                                                          
  *D. melanogaster*: Isogenic control line: y^1^w^1^                                                        Bloomington Drosophila Stock Center   BDSC: 1495; Flybase: FBst0001495
  *D. melanogaster*: wild-type line: Oregon-R-C                                                             Bloomington Drosophila Stock Center   BDSC: 5; Flybase: FBst0000005
  *D. melanogaster*: wild-type line: w^1118^                                                                Bloomington Drosophila Stock Center   BDSC: 5905; Flybase: FBst0005905
  *D. melanogaster*: GFP-tagged FoxO: w^1118^; PBac{y^+mDint2^w^+mC^ = foxo-GFP.FLAG}VK00037                Bloomington Drosophila Stock Center   BDSC\#38644; Flybase: FBst0038644
  *D. melanogaster*: *Stat92e* mutant: y^1^ w\*; ry\* e^1^ Stat92E^HJ^/TM3, Sb^1^                           Bloomington Drosophila Stock Center   BDSC\#24510; Flybase: FBst0024510
  *D. melanogaster*: *hop* mutant: y^1^w\*hop^3^/FM7c                                                       Bloomington Drosophila Stock Center   BDSC\#8495; Flybase: FBst0008495
  *D. melanogaster*: *vir-1* mutant: y^1^ w^67c23^; p{y^+mDint2^w^BR.E.BR^ = SUPor-P}vir-1^KG03668^         Bloomington Drosophila Stock Center   BDSC\#13292; Flybase: FBst0013292
  *D. melanogaster*: *Dicer-2* mutant: y^d2^ w^1118^ P{ey-FLP.N}2; Dcr-2^L811fsX^; P{Dcr-2^E1371K.t7.2^}3   Bloomington Drosophila Stock Center   BDSC\#32064; Flybase: FBst0032064
  *D. melanogaster*: *AGO2* mutant: w^1118^; AGO2^454^/TM3, Sb^1^ Ser^1^                                    Bloomington Drosophila Stock Center   BDSC\#36512; Flybase: FBst0036512
  *D. melanogaster*: *upd2* and *upd3* mutant: w\* upd2^Δ^ upd3^Δ^                                          Bloomington Drosophila Stock Center   BDSC\#55729; Flybase: FBst0055729
  *D. melanogaster*: *InR* RNAi: y^1^v^1^; P{TRiP.JF01482}attP2                                             Bloomington Drosophila Stock Center   BDSC\#31037; Flybase: FBst0031037
  *D. melanogaster*: *ilp7* mutant: w^1118^ TI{w^+mW.hs^ = TI}Ilp7^1^                                       Bloomington Drosophila Stock Center   BDSC\#30887; Flybase: FBst 0030887
  *D. melanogaster*: Actin driver line: y^1^w\*;P{Act5C-GAL4} 25FO1/CyO,y^+^                                Bloomington Drosophila Stock Center   BDSC: 4414 Flybase: FBst0004414
  *D. melanogaster*: *Tak1* mutant: Tak1^2527^                                                              Bloomington Drosophila Stock Center   BDSC\#58809; Flybase: FBst0058809
  *D. melanogaster: EGFR* mutant: Egfr^t1^ bw^1^/CyO                                                        Bloomington Drosophila Stock Center   BDSC\#2079; Flybase: FBst0002079
  Oligonucleotides                                                                                                                                
  *DmRp49* qRT-PCR:                                                                                         Integrated DNA Technologies           [@R103]
  Forward: CCACCAGTCGGATCGATATGC                                                                                                                  
  Reverse: CTCTTGAGAACGCAGGCGACC                                                                                                                  
  *DmDcr2* qRT-PCR:                                                                                         Integrated DNA Technologies           [@R103]
  Forward: GTATGGCGATAGTGTGACTGCGAC                                                                                                               
  Reverse: GCAGCTTGTTCCGCAGCAATATAGC                                                                                                              
  *DmAGO1* qRT-PCR:                                                                                         Integrated DNA Technologies           [@R103]
  Forward: GCTACAAGCCCCACCGCATC                                                                                                                   
  Reverse: CCCGATTTGCCGCTCTGCTC                                                                                                                   
  *DmAGO2* qRT-PCR:                                                                                         Integrated DNA Technologies           [@R103]
  Forward: CCGGAAGTGACTGTGACAGATCG                                                                                                                
  Reverse: CCTCCACGCACTGCATTGCTCG                                                                                                                 
  *DmInR* qRT-PCR:                                                                                          Integrated DNA Technologies           This study
  Forward: TTCACCCGCTACGCTATCTT                                                                                                                   
  Reverse: GCTGCAGAGCGACTTCTTAAA                                                                                                                  
  *DmVir-1* qRT-PCR:                                                                                        Integrated DNA Technologies           [@R25]
  Forward: GATCCCAATTTTCCCATCAA                                                                                                                   
  Reverse: GATTACAGCTGGGTGCACAA                                                                                                                   
  *DmUpd2* qRT-PCR:                                                                                         Integrated DNA Technologies           This study
  Forward: CCTATCCGAACAGCAATGGT                                                                                                                   
  Reverse: CTGGCGTGTGAAAGTTGAGA                                                                                                                   
  *DmUpd3* qRT-PCR:                                                                                         Integrated DNA Technologies           This study
  Forward: GCCCTCTTCACCAAACTGAA                                                                                                                   
  Reverse: TCGCCTTGCACAGACTCTTA                                                                                                                   
  *Cx18S* qRT-PCR:                                                                                          Integrated DNA Technologies           [@R92]
  Forward: CGCGGTAATTCCAGCTCCACTA                                                                                                                 
  Reverse: GCATCAAGCGCCACCATATAGG                                                                                                                 
  *CxR2D2* qRT-PCR:                                                                                         Integrated DNA Technologies           [@R85]
  Forward: GCAGGAAATTTGCGCCCGCC                                                                                                                   
  Reverse: CAAGTCTGGCCAAGCGCCGT                                                                                                                   
  *CxDcr2* qRT-PCR:                                                                                         Integrated DNA Technologies           This study
  Forward: TGCAAGGGCTGGAGATAAAG                                                                                                                   
  Reverse: TCAGGGTTTTCGTTTTACGG                                                                                                                   
  *CxSTAT* qRT-PCR:                                                                                         Integrated DNA Technologies           [@R60] and this study
  Forward: CAGATTCTGCACATCCAGCCGTTCACG                                                                                                            
  Reverse: GGCTTGTTCGGGTACAGGT                                                                                                                    
  WNV-Kun *env* qRT-PCR:                                                                                    Integrated DNA Technologies           This study
  Forward: TGGAGCATTCCGCTCATTGT                                                                                                                   
  Reverse: GAGGAACGTGAGGGCTATGG                                                                                                                   
  WNV-Kun *NS5* qRT-PCR:                                                                                    Integrated DNA Technologies           This study
  Forward: CTCTGCAAGCTCACTGGTCA                                                                                                                   
  Reverse: TGTCCAAAAGGGGTGGTGTC                                                                                                                   
  *DmERK* (*rolled*) dsRNA:                                                                                 Integrated DNA Technologies           [@R33]
  Forward: T7 + CTTTGGATTGGCTCGTATTG                                                                                                              
  Reverse: T7 + AGGATCATAATATTGCTCTAAATAG                                                                                                         
  T7 = TAATACGACTCACTATAGG                                                                                                                        
  Software and Algorithms                                                                                                                         
  Genome-Wide Association Study                                                                             [@R20]                                N/A
  Gene Set Enrichment Analysis (GSEA)                                                                       [@R106]                               N/A
  *D. melanogaster* gene ontology categories                                                                FlyBase                               Version fb_2016_04
  Prism                                                                                                     GraphPad                              Version 8

###### Highlights

-   Identified insulin-like receptor as anti-flaviviral in a screen of adult *Drosophila*

-   Insulin signaling inhibits antiviral RNAi while activating the JAK/STAT pathway

-   Flavivirus replication is reduced in mosquito cells primed with mammalian insulin

-   West Nile virus titer is reduced in *Culex* mosquitoes that are fed mammalian insulin
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